All lobbying filings

LMH STRATEGIC SOLUTIONS

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $50,000.00 income · posted Jul 5, 2026

Official filing document

Bills named in this filing 3

HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 1

Medicare/Medicaid

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.